MercyOne Dubuque

MercyOne Dubuque is a SAMHSA-registered addiction-treatment facility located at Dubuque, IA. The facility's programming is outpatient (IOP, MAT), not residential. Patient-level evaluation of this facility should distinguish three considerations: state licensure status, voluntary accreditation (CARF or Joint Commission), and clinical-framework alignment with current ASAM Criteria — each of which is independently verifiable.

Care levels at MercyOne Dubuque

MercyOne Dubuque is an outpatient-focused program (IOP, MAT) — patients live at home or in sober living and attend treatment sessions. This level of care is clinically appropriate for mild-to-moderate substance use disorder, or for patients stepping down from residential. ASAM Criteria 4e level-of-care matching requires clinical assessment across six dimensions (withdrawal potential, biomedical conditions, emotional/behavioral/cognitive conditions, readiness, relapse risk, recovery environment). The alignment of MercyOne Dubuque's offerings to any specific patient's clinical profile should be determined by an independent ASAM-aligned assessment prior to admission.

Insurance and payment

MercyOne Dubuque accepts both Medicaid and commercial insurance, which is the broadest payer profile and typically correlates with programs that operate at scale across the economic spectrum. The facility also accepts TRICARE or military benefits. Benefit verification should be obtained in writing prior to admission and should document: network contract status for the specific insurance product, prior authorization requirements and approved day-count, applicable cost-sharing structure, and out-of-network secondary coverage (where applicable). Proceeding on verbal VOB creates material risk of post-admission benefit dispute.

Before you call

Pre-admission due-diligence for MercyOne Dubuque: (1) ASAM 4e level-of-care documentation matching clinical assessment; (2) written Verification of Benefits specific to insurance product; (3) MAT policy documentation (particularly buprenorphine and methadone continuation protocols for opioid use disorder patients); (4) accreditation verification via CARF or Joint Commission provider-search tools; (5) state licensing status confirmed via IA behavioral-health regulator inspection records. The facility's documented pharmacotherapy offerings suggest MAT is available — confirm the specific medications and prescriber access during the admissions conversation.